Shengqiang Technology Secures Over RMB 1 Billion in Series B Funding to Advance Digital and Intelligent Pathology Solutions

VCBeat has learned at the earliest opportunity that,Shengqiang Technology, Industry Leader in Integrated Digital Smart Pathology Solutions, Completes Over RMB 100 Million Funding RoundBround of financing, which was led bySDIC MerchantsExclusive Investment.The funding from this round will be used for the team.Expansion, accelerate clinical validation and commercialization.

Shengqiang Technology Headquarters

Shenzhen Shengqiang Technology Co., Ltd. was established in 2013. Its founding team consists entirely of alumni from Tsinghua University. The company is a high-tech enterprise integrating research and development, production, and commercialization. Since its inception, the company has adhered to the development philosophy of becoming “the leader in digital pathology, the creator of informatized pathology, the integrator of intelligent pathology, and the advocate of functional pathology.” Shengqiang Technology maintains close collaborations with domestic and international research institutions, possesses sustainable innovation capabilities, and continuously tackles technical challenges. It has successfully developed digital and informatized solutions for pathology departments, including whole-slide imaging systems, fluorescence scanning imaging systems, and microscopic imaging information systems (MIIS).

The development of the digital pathology industry will transform traditional pathological workflow models, significantly enhancing the accuracy and efficiency of pathological diagnosis while promoting the sharing and collaboration of medical resources. Shenzhen Shengqiang Technology Co., Ltd. is committed to building an integrated ecosystem for the digitalization, informatization, and intelligentization of pathology, striving to advance standardization within the pathology sector. The company has established partnerships with over 100 hospitals, leading third-party diagnostic companies, and AI firms. It assists multiple top-tier tertiary Grade A hospitals in China in implementing comprehensive digital and intelligent solutions for their pathology departments, contributes to the construction of the national pathological standard database, and has developed a provincial pathological consultation platform centered on Anhui Provincial Hospital, thereby driving the advancement of digital and intelligent pathology in China.

Mr. Huang Qiang, General Manager of Shenzhen Shengqiang Technology Co., Ltd.Shenzhen Shengqiang Technology Co., Ltd. stated that the clinical pathology niche market is vast and offers numerous opportunities. After ten years of development, the company is now capable of providing customers with comprehensive, personalized smart pathology solutions and remains committed to becoming an innovative leader in the digital-intelligent pathology industry. The company expressed its sincere gratitude to the SDIC Merchants team for their recognition during this financing round, which also marks Shengqiang Technology’s entry into a new phase of development. Moving forward, the company will continue to increase investment in innovation and R&D to accelerate the development of new products and solutions, constantly enhance product quality and competitiveness, and promote the standardization of pathological diagnosis through digitization, informatization, and intelligent technologies, thereby comprehensively elevating the level of digital-intelligent transformation across all disciplines in Chinese pathology departments.

Meanwhile,Mr. Zhang Hongling, Sales Director of Shenzhen Shengqiang Technology Co., Ltd.The company will also intensify its efforts to expand in the pathology market, actively pursue various channels and opportunities to increase its market share, further develop international markets, explore new business opportunities, and establish close partnerships with renowned international collaborators, including Olympus.

SDIC MerchantsIt was stated that pathological examination, serving as the “doctor’s doctor,” is the “gold standard” for diagnosing the vast majority of diseases, particularly cancer. However, the current level of digital and intelligent transformation in pathology departments lags significantly behind that of the other two major diagnostic departments—clinical laboratories and radiology. Pathology remains the only hospital department not yet penetrated by digital and intelligent technologies. Shenzhen Shengqiang Technology Co., Ltd.’s pathology slide scanning imaging system, along with its corresponding informatization and intelligent technologies, can help hospital pathology departments improve diagnostic accuracy and work efficiency in the future. Currently, the key performance indicators of Shengqiang Technology’s products have surpassed those of similar offerings from large foreign life science instrument companies. Its products have been deployed in hundreds of Grade A tertiary hospitals in China, leading third-party diagnostic companies, and AI firms, representing an outstanding achievement within China’s domestic life science instrumentation industry. In the future, SDIC Capital will continue to support the company in strengthening its upstream supply chain and expanding into overseas markets, helping it become the leading enterprise providing one-stop digital and intelligent solutions for pathology departments in China.

SDIC Merchants is a leading private equity investment management firm in China, specializing in investments in the advanced manufacturing sector. It places significant emphasis on technological innovation and the value of outstanding entrepreneurs and their teams. The firm focuses its investments on key areas such as intelligent manufacturing, new energy intelligent vehicles, life sciences, and information and communications technology (ICT), committing to promote the green, digital, and service-oriented development of the manufacturing industry. The team’s cumulative assets under management exceed RMB 100 billion, with investors including financial institutions, the National Social Security Fund, and both state-owned and private capital.